DermTech Stock Forecast, Price & News

-0.65 (-1.89 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume351,949 shs
Average Volume727,767 shs
Market Capitalization$974.12 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DMTK News and Ratings via Email

Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter.

DermTech logo

About DermTech

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.79 out of 5 stars

Medical Sector

555th out of 2,221 stocks

Medical Laboratories Industry

10th out of 41 stocks

Analyst Opinion: 3.5Community Rank: 3.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

DermTech (NASDAQ:DMTK) Frequently Asked Questions

Is DermTech a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DermTech stock.
View analyst ratings for DermTech
or view top-rated stocks.

What stocks does MarketBeat like better than DermTech?

Wall Street analysts have given DermTech a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but DermTech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is DermTech's next earnings date?

DermTech is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for DermTech

How can I listen to DermTech's earnings call?

DermTech will be holding an earnings conference call on Wednesday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were DermTech's earnings last quarter?

DermTech, Inc. (NASDAQ:DMTK) posted its quarterly earnings results on Thursday, May, 13th. The company reported ($0.49) EPS for the quarter, missing the Zacks' consensus estimate of ($0.47) by $0.02. The business had revenue of $2.52 million for the quarter, compared to analyst estimates of $2 million. DermTech had a negative trailing twelve-month return on equity of 38.55% and a negative net margin of 631.63%.
View DermTech's earnings history

How has DermTech's stock been impacted by COVID-19 (Coronavirus)?

DermTech's stock was trading at $14.37 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DMTK shares have increased by 134.2% and is now trading at $33.66.
View which stocks have been most impacted by COVID-19

What price target have analysts set for DMTK?

7 Wall Street analysts have issued 1 year target prices for DermTech's shares. Their forecasts range from $20.00 to $79.00. On average, they anticipate DermTech's stock price to reach $56.00 in the next twelve months. This suggests a possible upside of 66.4% from the stock's current price.
View analysts' price targets for DermTech
or view top-rated stocks among Wall Street analysts.

Who are DermTech's key executives?

DermTech's management team includes the following people:
  • Dr. John D. Dobak, Pres, CEO & Director (Age 55, Pay $667.76k)
  • Mr. Kevin Sun M.B.A., CFO, Treasurer & Sec. (Age 43, Pay $378.15k)
  • Ms. Claudia Ibarra, Chief Operating Officer (Age 59, Pay $350.39k)
  • Dr. Zuxu Yao Ph.D., Chief Technical Officer (Age 58)
  • Mr. Michael Howell Ph.D., Chief Scientific Officer
  • Mr. Ray Akhavan J.D., Gen. Counsel
  • Ms. Sarah Dennison, VP of Marketing
  • Ms. Rachel Williams, VP & Head of People
  • Dr. Burkhard Jansen, Chief Medical Officer (Age 55)
  • Mr. Todd Michael Wood, Chief Commercial Officer (Age 52)

Who are some of DermTech's key competitors?

What other stocks do shareholders of DermTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Momo (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH).

What is DermTech's stock symbol?

DermTech trades on the NASDAQ under the ticker symbol "DMTK."

Who are DermTech's major shareholders?

DermTech's stock is owned by a number of retail and institutional investors. Top institutional investors include Kornitzer Capital Management Inc. KS (0.75%), Avalon Investment & Advisory (0.25%), Alliancebernstein L.P. (0.09%) and Kovack Advisors Inc. (0.02%). Company insiders that own DermTech stock include Burkhard Jansen, Claudia Ibarra, Enrico Picozza, John Dobak, Kevin M Sun, Matthew L Posard, Mutual Insurance Co Donegal, Rtw Investments, Lp, Scott R Pancoast and Todd Michael Wood.
View institutional ownership trends for DermTech

Which institutional investors are buying DermTech stock?

DMTK stock was acquired by a variety of institutional investors in the last quarter, including Avalon Investment & Advisory, Kornitzer Capital Management Inc. KS, Alliancebernstein L.P., and Kovack Advisors Inc.. Company insiders that have bought DermTech stock in the last two years include Enrico Picozza, Matthew L Posard, Mutual Insurance Co Donegal, and Rtw Investments, Lp.
View insider buying and selling activity for DermTech
or or view top insider-buying stocks.

How do I buy shares of DermTech?

Shares of DMTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DermTech's stock price today?

One share of DMTK stock can currently be purchased for approximately $33.66.

How much money does DermTech make?

DermTech has a market capitalization of $974.12 million and generates $5.89 million in revenue each year. The company earns $-35,250,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.

How many employees does DermTech have?

DermTech employs 114 workers across the globe.

What is DermTech's official website?

The official website for DermTech is

Where are DermTech's headquarters?

DermTech is headquartered at 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037.

How can I contact DermTech?

DermTech's mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The company can be reached via phone at 858-450-4222 or via email at [email protected]

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.